 |
| Daiichi Sankyo CEO Joji Nakayama |
Japan's Daiichi Sankyo has licensed a candidate to treat ischemic stroke, TS23, from Memphis-based Translational Sciences without disclosing any details on fees, milestones and royalties for exclusive global development and commercial rights. The company said in a press release that the aim for the candidate in Phase I clinical trials is to develop a novel thrombus (blood clot) dissolving agent. "Daiichi Sankyo recognized the great potential of this novel therapy," said Guy Reed, chief scientific officer and CEO of Translational Services. "We believe they have the expertise and resources to fully develop it for the millions of patients each year who suffer cardiovascular disease and stroke. We are enormously grateful to the National Institutes of Health who provided crucial support to translate this research into therapy." Release